Our products

Despite efforts on its prevention and its diagnostic, colorectal cancer remains one of the most frequent cause of death by cancer worldwide. Therefore, we decided to target metastatic colorectal cancer which represents the 3rd incidence of cancers and with very poor prognostic.

Although surgery offers the best option for early-stage diagnosed diseases, treatment of late stage (OMS grade IV) colorectal cancer, named metastatic colorectal cancer, relies on combination of chemotherapies. Strategies are limited to increase 5-year-survival rate because of decreasing efficacy and tolerance along time.
Furthermore, use of immune checkpoint inhibitors is limited to very specific molecular phenotypes (mismatch repair-deficient (dMMR) and/or microsatellite instability-high (MSI-H) tumors). Although efficient, their prescription is limited to 10 to 20% of patients suffering colorectal cancer.

Through intradermal injection, STC-1010 would be added to standards of care including chemotherapies, Anti angiogenics or anti-EGF-R, or Immune Checkpoints Inhibitors .

We obtain very promising results in vivo on both inhibition of tumor growth and increase of survival.
We do expect First mCRC patient to benefit from STC-1010 by early 2022 in a clinical trial setting.

STC-1010

STC-1010 acts on a synergistic add-on treatment with existing and coming therapeutic strategies. STC-1010 aims to stimulate patient’s own immune system bypassing tumour’s immunotolerance and drug resistance mechanisms occurring in solid cancers.
In addition to its stand-alone activity, STC-1010 could have a potential synergistic effect when combined to Immune Checkpoint Inhibitors like Anti PDL-1, anti PD-1 or CTLA4. This assumption needs to be further assessed in different models in 2020.

Solid Tumours

Because of its mode of action, efficacy would be expected in other solid tumours.
Brenus Pharma would like to expand its know-how to other indications in future.
STC-1010 acts on a synergistic add-on treatment with existing and coming therapeutic strategies. STC-1010 aims to stimulate patient’s own immune system bypassing tumour’s immunotolerance and drug resistance mechanisms occurring in solid cancers.
In addition to its stand-alone activity, STC-1010 could have a potential synergistic  effect when combined to Immune Checkpoint Inhibitors like Anti PDL-1, anti PD-1 or CTLA4. This assumption needs to be further assessed in different models in 2020.